Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Estey, E' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 222 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nguyen, Q; Estey, E; Raad, I; Rolston, K; Kantarjian, H; Jacobson, K; Konoplev, S; Ghosh, S; Luna, M; Tarrand, J; Whimbey, E
      Cytomegalovirus pneumonia in adults with leukemia: An emerging problem

      CLINICAL INFECTIOUS DISEASES
    2. Estey, E; Koller, C; Cortes, J; Reed, P; Freireich, E; Giles, F; Kantarjian, H
      Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid

      LEUKEMIA & LYMPHOMA
    3. Verstovsek, S; Estey, E; Manshouri, T; Keating, M; Kantarjian, H; Giles, FJ; Albitar, M
      High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome

      LEUKEMIA & LYMPHOMA
    4. Giles, FJ; Shen, Y; Kantarjian, HM; Korbling, MJ; O'Brien, S; Anderlini, P; Donato, M; Pierce, S; Keating, MJ; Freireich, EJ; Estey, E
      Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival

      LEUKEMIA & LYMPHOMA
    5. Fleming, RV; Kantarjian, HM; Husni, R; Rolston, K; Lim, J; Raad, I; Pierce, S; Cortes, J; Estey, E
      Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia

      LEUKEMIA & LYMPHOMA
    6. Verstovsek, S; Kantarjian, H; Estey, E; Aguayo, A; Giles, FJ; Manshouri, T; Koller, C; Estrov, Z; Freireich, E; Keating, M; Albitar, M
      Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

      LEUKEMIA
    7. Sarriera, JE; Albitar, M; Estrov, Z; Gidel, C; Aboul-Nasr, R; Manshouri, T; Kornblau, S; Chang, KS; Kantarjian, H; Estey, E
      Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing

      LEUKEMIA
    8. Verstovsek, S; Manshouri, T; Kantarjian, H; Giles, FJ; Keating, M; Estey, E; Albitar, M
      Highly reproducible detection and semi-quantification of telomerase activity

      BIOTECHNIQUES
    9. Greenberg, P; Anderson, J; Estey, E; Fenaux, P; Hamblin, T; Hellstrom-Lindberg, E; List, A; Ohyashiki, K; Sanz, G; Zanz, M
      Classifying chronic myelomonocytic leukemia - In Reply

      JOURNAL OF CLINICAL ONCOLOGY
    10. Sievers, EL; Larson, RA; Stadtmauer, EA; Estey, E; Lowenberg, B; Dombret, H; Karanes, C; Theobald, M; Bennett, JM; Sherman, ML; Berger, MS; Eten, CB; Loken, MR; van Dongen, JJM; Bernstein, ID; Appelbaum, FR
      Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

      JOURNAL OF CLINICAL ONCOLOGY
    11. Giles, F; Cortes, J; Garcia-Manero, G; Kornblau, S; Estey, E; Kwari, M; Murgo, A; Kantarjian, H
      Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

      INVESTIGATIONAL NEW DRUGS
    12. Estey, E
      Reducing mortality associated with immediate treatment complications of adult leukemias

      SEMINARS IN HEMATOLOGY
    13. Milella, M; Kornblau, SM; Estrov, Z; Carter, BZ; Lapillonne, H; Harris, D; Konopleva, M; Zhao, SR; Estey, E; Andreeff, M
      Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

      JOURNAL OF CLINICAL INVESTIGATION
    14. Cortes, J; Estey, E; O'Brien, S; Giles, F; Shen, Y; Koller, C; Beran, M; Thomas, D; Keating, M; Kantarjian, H
      High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

      CANCER
    15. Verstovsek, S; Kantarjian, H; Aguayo, A; Manshouri, T; Freireich, E; Keating, M; Estey, E; Albitar, M
      Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

      BRITISH JOURNAL OF HAEMATOLOGY
    16. Douer, D; Estey, E; Santillana, S; Bennett, JM; Lopez-Bernstein, G; Boehm, K; Williams, T
      Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

      BLOOD
    17. Estey, E; Cortes, J; Beran, M; Koller, CA; Keating, MJ
      AML in the elderly

      ACUTE LEUKEMIAS VIII: PROGNOSTIC FACTORS AND TREATMENT STRATEGIES
    18. Cortes, J; Estey, E; Beran, M; O'Brien, S; Giles, F; Koller, C; Keating, M; Kantarjian, H
      Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

      LEUKEMIA & LYMPHOMA
    19. O'Donnell, MR; Appelbaum, FR; Baer, MR; Carabasi, MH; Coutre, SE; Erba, HP; Estey, E; Glenn, MJ; Kraut, EH; Maslak, P; Millenson, M; Miller, CB; Saba, HI; Stone, R; Tallman, MS
      NCCN Practice Guidelines for acute myelogenous leukemia

      ONCOLOGY-NEW YORK
    20. Greenberg, P; Anderson, J; de Witte, T; Estey, E; Fenaux, P; Gupta, P; Hamblin, T; Hellstrom-Lindberg, E; List, A; Mufti, G; Neuwirtova, R; Ohyashiki, K; Oscier, D; Sanz, G; Sanz, M; Willman, C
      Problematic WHO reclassification of myelodysplastic syndromes

      JOURNAL OF CLINICAL ONCOLOGY
    21. Keyhani, A; Huh, YO; Jendiroba, D; Pagliaro, L; Cortez, J; Pierce, S; Pearlman, M; Estey, E; Kantarjian, H; Freireich, EJ
      Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

      LEUKEMIA RESEARCH
    22. Faderl, S; Kantarjian, HM; Estey, E; Manshouri, T; Chan, CY; Elsaied, AR; Kornblau, SM; Cortes, J; Thomas, DA; Pierce, S; Keating, MJ; Estrov, Z; Albitar, M
      The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia

      CANCER
    23. Aguayo, A; Kantarjian, H; Manshouri, T; Gidel, C; Estey, E; Thomas, D; Koller, C; Estrov, Z; O'Brien, S; Keating, M; Freireich, E; Albitar, M
      Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

      BLOOD
    24. Albitar, M; Beran, M; O'Brien, S; Kantarjian, H; Frieriech, E; Keating, M; Estey, E
      Differences between refractory anemia with excess blasts in transformationand acute myeloid leukemia

      BLOOD
    25. Kornblau, SM; Thall, PF; Estrov, Z; Walterscheid, M; Patel, S; Theriault, A; Keating, MJ; Kantarjian, H; Estey, E; Andreeff, M
      The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics

      CLINICAL CANCER RESEARCH
    26. Wilhelm, M; O'Brien, S; Rios, MB; Estey, E; Keating, MJ; Plunkett, W; Sorenson, M; Kantarjian, HM
      Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase

      LEUKEMIA & LYMPHOMA
    27. Vey, N; Kantarjian, H; Tran, H; Beran, M; O'Brien, S; Bivins, C; Giles, F; Cortes, J; Cheson, B; Arbuck, S; Estey, E
      Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia

      ANNALS OF ONCOLOGY
    28. Beran, M; Estey, E; O'Brien, S; Cortes, J; Koller, CA; Giles, FJ; Kornblau, S; Andreeff, M; Vey, N; Pierce, SR; Hayes, K; Wong, GC; Keating, M; Kantarjian, H
      Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    29. Murray, CK; Estey, E; Paietta, E; Howard, RS; Edenfield, WJ; Pierce, S; Mann, KP; Bolan, C; Byrd, JC
      CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?

      JOURNAL OF CLINICAL ONCOLOGY
    30. Cortes, J; O'Brien, S; Estey, E; Giles, F; Keating, M; Kantarjian, H
      Phase I study of liposomal daunorubicin in patients with acute leukemia

      INVESTIGATIONAL NEW DRUGS
    31. Vey, N; Kantarjian, H; Beran, M; O'Brien, S; Cortes, J; Koller, C; Estey, E
      Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

      INVESTIGATIONAL NEW DRUGS
    32. Albitar, M; Manshouri, T; Kantarjian, H; Keating, M; Estrov, Z; Faber, J; Freireich, EJ; Pierce, S; Estey, E
      Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia

      LEUKEMIA RESEARCH
    33. Albitar, M; Chang, KS; Pierce, S; Kantarjian, H; Estey, E
      The short form of PML-RAR alpha fusion transcript is associated with poor survival

      LEUKEMIA RESEARCH
    34. Ravandi-Kashani, F; Estey, E; Cortes, J; Medeiros, LJ; Giles, FJ
      Granulocytic sarcoma of the pancreas: a report of two cases and literaturereview

      CLINICAL AND LABORATORY HAEMATOLOGY
    35. Koller, CA; Kantarjian, HM; Feldman, EJ; O'Brien, S; Rios, MB; Estey, E; Keating, M
      A Phase I-II trial of escalating doses of mitoxantrone with fixed doses ofcytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

      CANCER
    36. Aguayo, A; Estey, E; Kantarjian, H; Mansouri, T; Gidel, C; Keating, M; Giles, F; Estrov, Z; Barlogie, B; Albitar, M
      Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia

      BLOOD
    37. Vey, N; Keating, M; Giles, F; Cortes, J; Beran, M; Estey, E
      Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy

      BLOOD
    38. KORNBLAU SM; ANDREEFF M; HU SX; XU HJ; PATEL S; THERIAULT A; KOLLER C; KANTARJIAN H; ESTEY E; DEISSEROTH AB; BENEDICT WF
      LOW AND MAXIMALLY PHOSPHORYLATED LEVELS OF THE RETINOBLASTOMA PROTEINCONFER POOR-PROGNOSIS IN NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA -A PROSPECTIVE-STUDY

      Clinical cancer research
    39. GANDHI V; XU YZ; ESTEY E
      ACCUMULATION OF ARABINOSYLURACIL 5'-TRIPHOSPHATE DURING ARABINOSYLCYTOSINE THERAPY IN CIRCULATING BLASTS OF PATIENTS WITH ACUTE MYELOGENOUSLEUKEMIA

      Clinical cancer research
    40. KORNBLAU SM; KANTARJIAN H; OBRIEN S; ANDREEFF M; KOLLER CA; BERAN M; KEATING M; ESTEY E
      CECA-CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN AND CYTOSINE-ARABINOSIDE - A NEW SALVAGE REGIMEN FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUSLEUKEMIA

      Leukemia & lymphoma
    41. Beran, M; Estey, E; O'Brien, SM; Giles, FJ; Koller, CA; Kornblau, S; Keating, M; Kantarjian, HM
      Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    42. ESTEY E
      RESPONSE FROM ESTEY TO THOMAS,X ET-AL

      Leukemia
    43. KEATING MJ; OBRIEN S; LERNER S; KOLLER C; BERAN M; ROBERTSON LE; FREIREICH EJ; ESTEY E; KANTARJIAN H
      LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC-LYMPHOCYTIC-LEUKEMIA (CLL) RECEIVING FLUDARABINE REGIMENS AS INITIAL THERAPY

      Blood
    44. DELIMA M; ALBITAR M; OBRIEN S; PIERCE S; KANTARJIAN H; ANDREEFF M; FAYAD L; KEATING M; ESTEY E
      COMPARISON OF REFERRING AND TERTIARY CANCER CENTER PHYSICIANS DIAGNOSES IN PATIENTS WITH LEUKEMIA

      The American journal of medicine
    45. GANDHI V; ESTEY E; DU M; KEATING MJ; PLUNKETT W
      MINIMUM DOSE OF FLUDARABINE FOR THE MAXIMAL MODULATION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE IN HUMAN LEUKEMIA BLASTS DURING THERAPY

      Clinical cancer research
    46. ESTEY E
      PROGNOSTIC FACTORS IN CLINICAL CANCER TRIALS

      Clinical cancer research
    47. BERAN M; JEHA S; OBRIEN S; ESTEY E; VITEK L; ZURLO MG; RIOS MB; KEATING M; KANTARJIAN H
      TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY

      Clinical cancer research
    48. RODRIGUEZ CO; LEGHA JK; ESTEY E; KEATING MJ; GANDHI V
      PHARMACOLOGICAL AND BIOCHEMICAL STRATEGIES TO INCREASE THE ACCUMULATION OF ARABINOFURANOSYLGUANINE TRIPHOSPHATE IN PRIMARY HUMAN LEUKEMIA-CELLS

      Clinical cancer research
    49. CORTES J; KANTARJIAN H; OBRIEN S; BERAN M; ESTEY E; KEATING M; TALPAZ M
      A PILOT-STUDY OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    50. HOFF PM; PIERCE S; ESTEY E
      COMPARISON OF ACUTE MYELOID-LEUKEMIA PATIENTS AT MD ANDERSON - 1982-1986 VS 1992-1996

      Leukemia
    51. SACCHI S; KANTARJIAN HM; OBRIEN S; BERAN M; KOLLER C; PIERCE S; KORNBLAU S; ESTEY E; KEATING MJ; TALPAZ M
      LONG-TERM FOLLOW-UP RESULTS OF ALPHA-INTERFERON-BASED REGIMENS IN PATIENTS WITH LATE CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    52. KANTARJIAN HM; OBRIEN SM; KEATING M; BERAN M; ESTEY E; GIRALT S; KORNBLAU S; RIOS MB; DEVOS D; TALPAZ M
      RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    53. ESTEY E; THALL P; KANTARJIAN H; PIERCE S; KORNBLAU S; KEATING M
      ASSOCIATION BETWEEN INCREASED BODY-MASS INDEX AND A DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA

      Leukemia
    54. BSEISO AW; KANTARJIAN H; ESTEY E
      MYELODYSPLASTIC SYNDROME FOLLOWING SUCCESSFUL THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA

      Leukemia
    55. KANTARJIAN HM; OBRIEN SM; ESTEY E; GIRALT S; BERAN M; RIOS MB; KEATING M; DEVOS D; TALPAZ M
      DECITABINE STUDIES IN CHRONIC AND ACUTE MYELOGENOUS LEUKEMIA

      Leukemia
    56. ESTEY E; THALL PF; PIERCE S; KANTARJIAN H; KEATING M
      COMPARING AN APPLE TO A FRUIT SALAD - REPLY

      Journal of clinical oncology
    57. KORNBLAU SM; ESTEY E; MADDEN T; TRON HT; ZHAO S; CONSOLI U; SNELL V; SANCHEZWILLIAMS G; KANTARJIAN H; KEATING M; NEWMAN RA; ANDREEFF M
      PHASE-I STUDY OF MITOXANTRONE PLUS ETOPOSIDE WITH MULTIDRUG BLOCKADE BY SDZ PSC-833 IN RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    58. KURZROCK R; STROM SS; ESTEY E; OBRIEN S; KEATING MJ; JIANG H; ADAMS T; TALPAZ M
      2ND CANCER RISK IN HAIRY-CELL LEUKEMIA - ANALYSIS OF 350 PATIENTS

      Journal of clinical oncology
    59. ESTEY E; THALL PF; PIERCE S; KANTARJIAN H; KEATING M
      TREATMENT OF NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA WITHOUT CYTARABINE

      Journal of clinical oncology
    60. ESTEY E; THALL P; DAVID C
      DESIGN AND ANALYSIS OF TRIALS OF SALVAGE THERAPY IN ACUTE MYELOGENOUSLEUKEMIA

      Cancer chemotherapy and pharmacology
    61. WETZLER M; KURZROCK R; ESTROV Z; BARONE S; ESTEY E; TALPAZ M
      SUPPRESSED FORMATION OF BONE-MARROW ADHERENT LAYERS DERIVED FROM ACUTE MYELOID-LEUKEMIA PATIENTS AFTER IN-VITRO EXPOSURE TO INTERLEUKIN-4

      Leukemia research
    62. ESTEY E; DELIMA M; STROM S; PIERCE S; FREIREICH EJ; KEATING MJ
      LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID-LEUKEMIA TREATED AT THE UNIVERSITY-OF-TEXAS M.-D.-ANDERSON-CANCER-CENTER

      Cancer
    63. ESTEY E; THALL P; BERAN M; KANTARJIAN H; PIERCE S; KEATING M
      EFFECT OF DIAGNOSIS (REFRACTORY-ANEMIA WITH EXCESS BLASTS, REFRACTORY-ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION, OR ACUTE MYELOID-LEUKEMIA [AML]) ON OUTCOME OF AML-TYPE CHEMOTHERAPY

      Blood
    64. ESTEY E; KEATING M; PIERCE S; BERAN M
      APPLICATION OF THE INTERNATIONAL SCORING SYSTEM FOR MYELODYSPLASIA TOM.D.-ANDERSON PATIENTS

      Blood
    65. DELIMA M; STROM SS; KEATING M; KANTARJIAN H; PIERCE S; OBRIEN S; FREIREICH E; ESTEY E
      IMPLICATIONS OF POTENTIAL CURE IN ACUTE MYELOGENOUS LEUKEMIA - DEVELOPMENT OF SUBSEQUENT CANCER AND RETURN TO WORK

      Blood
    66. FLEMING R; KANTARJIAN H; LICHTIGER B; KEATING M; ESTEY E
      GRANULOCYTE TRANSFUSIONS FROM GM-CSF TREATED DONORS AS INFECTION PROPHYLAXIS IN AML MDS DURING INDUCTION/

      Blood
    67. DABAJA BS; KANTARJIAN H; OBRIEN S; ESTEY E; KEATING M
      DELETION OR LOSSES IN CHROMOSOME-5 OR CHROMOSOME-7 IN ADULTS WITH ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - INCIDENCE, ASSOCIATIONS AND IMPLICATIONS

      Blood
    68. KORNBLAU SM; THALL P; WALTERSCHEID M; ESTROV Z; KEATING M; PATEL S; KANTARJIAN H; ESTEY E; ANDREEFF M
      ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS WITH LOWER LEVELS OF BCL2 EXPRESSION AND UNFAVORABLE CYTOGENETICS HAVE A VERY POOR-PROGNOSIS

      Blood
    69. WEINKAUFF R; STAROSTIK P; HAYES K; HUH YO; HIRSCHGINSBERG C; BUESORAMOS C; ANDREEFF M; KEATING M; KANTARJIAN H; FREIREICH E; ESTEY E; ALBITAR M
      USE OF PERIPHERAL-BLOOD BLASTS VERSUS BONE-MARROW BLASTS FOR DIAGNOSIS OF ACUTE-LEUKEMIA

      Blood
    70. DABAJA B; KANTARJIAN H; PIERCE S; KEATING M; ESTEY E
      THE OUTCOME OF FUO DURING INDUCTION THERAPY OF AML MDS/

      Blood
    71. CORTES J; KANTARJIAN H; OBRIEN S; ANDREEFF M; ESTEY E; KEATING M
      METHOTREXATE, VINCRISTINE, PEG-ASPARAGINASE AND PREDNISONE (MOAP) FORPATIENTS (PTS) WITH REFRACTORY OR RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)

      Blood
    72. KOLLER CA; KANTARJIAN H; FELDMAN E; ESTEY E; OBRIEN S; RIOS MB; KEATING M
      A PHASE I II TRIAL OF INCREASING DOSES OF MITOXANTRONE WITH FLUDARABINE AND CYTARABINE (FAM REGIMEN) IN RELAPSED ACUTE-LEUKEMIA AND CHRONICMYELOGENEOUS LEUKEMIA IN BLASTIC PHASE (CML-BP)/

      Blood
    73. THOMAS D; KANTARJIAN H; OBRIEN S; KEATING MJ; KOLLER C; BERAN M; ESTEY E; PIERCE S; FREIREICH E
      REFRACTORY OR RELAPSED BURKITTS TYPE ADULT LYMPHOBLASTIC-LEUKEMIA (ALL) - CHARACTERISTICS AND OUTCOME WITH SALVAGE THERAPY

      Blood
    74. THOMAS D; KANTARJIAN H; KOLLER C; OBRIEN S; KEATING MJ; BERAN M; ESTEY E; PIERCE S; FREIREICH E
      REVIEW OF 43 PATIENTS (PTS) WITH ADULT LYMPHOBLASTIC-LEUKEMIA (ALL) IN RELAPSE AFTER INITIAL CR DURATION GREATER-THAN-2 YEARS - CHARACTERISTICS, RESPONSE AND OUTCOME WITH SALVAGE THERAPY

      Blood
    75. KANTARJIAN H; MANSHOURI PT; ESTROV Z; TALPAZ M; OBRIEN S; BERAN M; PIERCE S; ESTEY E; KEATING M; ALBITAR M
      SIGNIFICANCE OF C-MPL EXPRESSION IN PHILADELPHIA-CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    76. KLICHE KO; SARRIS AH; ESTEY E; SNELL V; ANDREEFF M
      INTERLEUKIN-10 PLASMA-LEVELS ARE FREQUENTLY ELEVATED IN MDS AND ACUTEAND CHRONIC MYELOID LEUKEMIAS

      Blood
    77. ALBITAR M; MANSHOURI T; KANTARJIAN H; KEATING M; ESTROV Z; FABER J; FREIREICH E; PIERCE S; ESTEY E
      FAVORABLE CYTOGENETIC GROUPS IN ACUTE MYELOID-LEUKEMIA (AML) DO NOT OVEREXPRESS C-MPL PROTEIN

      Blood
    78. RAVANDI F; KEATING M; PIERCE S; ESTEY E
      IDENTIFICATION OF A RELATIVELY FAVORABLE GROUP WITHIN AML MDS PTS WITH CHROMOSOME-5 AND/OR 7 ABNORMALITIES/

      Blood
    79. CORTES J; KANTARJIAN H; KEATING M; OBRIEN S; RODRIGUEZ J; PIERCE S; ESTEY E
      BETA-2-MICROGLOBULIN (B2M) IS A SIGNIFICANT PROGNOSTIC FACTOR FOR OUTCOME OF PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA(AML) AND MYELODYSPLASTIC SYNDROME (MDS)

      Blood
    80. ESTROV Z; THALL P; ESTEY E; KANTARJIAN H; HARRIS D; VAN Q; WALTERSCHEID M; TALPAZ M; KORNBLAU S
      A COMBINED HIGH-PROTEIN LEVEL OF BOTH CASPASE-2 (ICH-1) AND CASPASE-3(CPP32) IS A MAJOR UNFAVORABLE PROGNOSTIC FACTOR IN ACUTE MYELOGENOUSLEUKEMIA (AML)

      Blood
    81. ANDREEFF M; ZHAO S; KONOPLEVA M; XIE Z; ZHANG X; SNELL V; MCQUEEN T; JIANG S; KLICHE KO; SCHENK T; WEIDNER D; ESTEY E; THALL P; SANCHEZWILLIAMS G; KORNBLAU SM; REED JC
      THE ROLE OF BCL-2 APOPTOSIS REGULATING GENES IN ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    82. KONOPLEVA M; MIKHAIL A; ESTROV Z; ZHAO S; HARRIS D; SANCHEZWILLIAMS G; KORNBLAU S; JUNG J; KLICHE KO; JIANG S; PRZEPIORKA D; SNODGRASS HR; ESTEY E; ANDREEFF M
      A FUNCTIONAL RECEPTOR IN AML - CORRELATION OF EXPRESSION WITH BLAST COUNT AND FAB M1

      Blood
    83. KORNBLAU SM; THALL P; ESTROV Z; KANTARJIAN H; ESTEY E; ANDREEFF M
      PROLIFERATION AND APOPTOSIS REGULATING PROTEINS AND CYTOGENETICS PREDICT PROGNOSIS IN ACUTE MYELOGENOUS LEUKEMIA (AML)

      Blood
    84. KORNBLAU SM; LE XF; ESTEY E; ANDREEFF M; GRONER Y; CHANG KS
      EXPRESSION OF AML-2 PROTEIN IS HIGHLY PROGNOSTIC IN ACUTE MYELOGENOUSLEUKEMIA (AML) FAB-M2

      Blood
    85. ESTEY E; THALL P; KANTARJIAN H; PIERCE S; KEATING M
      THE VALUE OF CR IN NEWLY-DIAGNOSED AML

      Blood
    86. ESTEY E; DOUER D; WIERNIK P; REED P; THOMPSON J; GORDON D
      TREATMENT OF RECURRENT ACUTE PROMYELOCYTIC LEUKEMIA (APL) WITH LIPOSOMAL ALL-TRANS-RETINOIC ACID (L-ATRA)

      Blood
    87. ESTEY E; BERAN M; PIERCE S; KANTARJIAN H; KEATING M
      ALL-TRANS-RETINOIC ACID (ATRA) MAY IMPROVE RESULTS OF CHEMOTHERAPY INPOOR-PROGNOSIS NON-APL AML AND MDS - A RANDOMIZED STUDY

      Blood
    88. CORTES J; KANTARJIAN H; BERAN M; OBRIEN S; KOLLER C; KORNBLAU S; ANDREEFF M; KEATING M; FREIREICH EJ; ESTEY E
      CYCLOPHOSPHAMIDE (CTX), ARA-C AND TOPOTECAN (TOP) (CAT) IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED ACUTE LEUKEMIAS AND TRANSFORMED CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    89. CORTES J; KANTARJIAN H; OBRIEN S; KEATING M; ESTEY E
      INTERLEUKIN-2 (IL2) THERAPY FOR ADULT PATIENTS (PTS) WITH ACUTE MYELOGENOUS LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR)

      Blood
    90. ESTEY E; DAHLBERG S; KANTARJIAN H; REED P; PIERCE S; MACPHERSON B; BIANCO J; SINGER J; KEATING M
      RANDOMIZED TRIAL OF IDARUBICIN PLUS ARA-C + -LISOFYLLINE IN NEWLY-DISGNOSED AML/MDS/

      Blood
    91. CHOUDHURY A; AGUSALA K; SUTARIA S; ESTEY E; CHAMPLIN R; CLAXTON D
      LEUKEMIC DENDRITIC CELLS DERIVED IN-VITRO FROM AML PATIENTS CAN STIMULATE ANTILEUKEMIC ACTIVITY IN AUTOLOGOUS T-CELL POPULATIONS

      Blood
    92. FAYAD L; KURZROCK R; KEATING M; OBRIEN S; KANTARJIAN H; ANDREEFF M; PIERCE S; TALPAZ M; FREIREICH E; ESTEY E
      TREATMENT OF HAIRY-CELL LEUKEMIA (HCL) WITH 2-CDA - LONG-TERM FOLLOW-UP AT M.D.-ANDERSON-CANCER-CENTER

      Blood
    93. BERAN M; KANTARJIAN H; KEATING M; OBRIEN S; PIERCE S; KOLLER C; CORTES J; ANDREEFF M; KORNBLAU S; ESTEY E
      RESULTS OF COMBINATION CHEMOTHERAPY WITH TOPOTECAN AND HIGH-DOSE CYTOSINE-ARABINOSIDE (ARA-C) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

      Blood
    94. GIRALT S; ESTEY E; ALBITAR M; VANBESIEN K; RONDON G; ANDERLINI P; OBRIEN S; KHOURI I; GAJEWSKI J; MEHRA R; CLAXTON D; ANDERSSON B; BERAN M; PRZEPIORKA D; KOLLER C; KORNBLAU S; KORBLING M; KEATING M; KANTARJIAN H; CHAMPLIN R
      ENGRAFTMENT OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS WITH PURINE ANALOG-CONTAINING CHEMOTHERAPY - HARNESSING GRAFT-VERSUS-LEUKEMIA WITHOUT MYELOABLATIVE THERAPY

      Blood
    95. KEATING MJ; OBRIEN S; MCLAUGHLIN P; DIMOPOULOS M; GANDHI V; PLUNKETT W; LERNER S; KANTARJIAN H; ESTEY E
      CLINICAL-EXPERIENCE WITH FLUDARABINE IN HEMATOONCOLOGY

      HEMATOLOGY AND CELL THERAPY
    96. ZHANG W; PIATYSZEK MA; KOBAYASHI T; ESTEY E; ANDREEFF M; DEISSEROTH AB; WRIGHT WE; SHAY JW
      TELOMERASE ACTIVITY IN HUMAN ACUTE MYELOGENOUS LEUKEMIA - INHIBITION OF TELOMERASE ACTIVITY BY DIFFERENTIATION-INDUCING AGENTS

      Clinical cancer research
    97. ESTEY E
      TREATMENT OF REFRACTORY AML

      Leukemia
    98. KORNBLAU SM; GANDHI V; ANDREEFF HM; BERAN M; KANTARJIAN HM; KOLLER CA; OBRIEN S; PLUNKETT W; ESTEY E
      CLINICAL AND LABORATORY STUDIES OF 2-CHLORODEOXYADENOSINE+ -CYTOSINE-ARABINOSIDE FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA IN ADULTS/

      Leukemia
    99. ESTEY E
      TREATMENT OF REFRACTORY AML

      Leukemia
    100. ANDERLINI P; PIERCE S; KANTARJIAN H; ESTEY E
      ACUTE MYELOID LEUKEMIA-TYPE CHEMOTHERAPY FOR MYELODYSPLASIA

      Journal of clinical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 04:25:21